Plenary: Methamphetamine Now: Clinical Realities and Treatment Frontiers
| Monday, November 9, 2026 |
| 11:00 AM - 12:10 PM |
Speaker
Prof Nadine Ezard
Director
National Centre for Clinical Research on Emerging Drugs
Opening - Australian Framing
11:00 AM - 11:10 AMBiography
Professor Nadine Ezard is an Addiction Medicine Specialist (MBBS, BA, MPH, PhD, FAChAM), inaugural Director of the Australian National Centre for Clinical Research on Emerging Drugs (NCCRED), and Clinical Director of the Alcohol and Drug Service at St Vincent’s Hospital Sydney. Her clinical work serves people with a variety of substance use disorders in inpatient, outpatient and community settings, and strives to embed research into clinical practice. Nadine has more than 30 years of clinical and research experience in addiction medicine and public health practice in Australian and international contexts including for the World Health Organization, the United Nations High Commissioner for Refugees, and the United Nations Office of Drugs and Crime. She is a worldwide recognised researcher in substance use and its translation into consumer-focused harm-reduction public health interventions, models of care and policy for marginalised populations.
Prof Nadine Ezard
Director
National Centre for Clinical Research on Emerging Drugs
Dr. Didier Jutras-Aswad
Professor
Université de Montréal/CHUM
Fireside Chat
11:10 AM - 11:50 AMBiography
Didier Jutras-Aswad is an addiction psychiatrist and Professor of Psychiatry and Addictology at Université de Montréal, as well as Chief of the Department of Psychiatry at the Centre hospitalier de l’Université de Montréal (CHUM). He is also a Principal Scientist at the CHUM Research Centre and the Nominated Principal Investigator leading the Quebec node of the Canadian Research Initiative in Substance Matters network. Dr. Jutras-Aswad’s clinical and research work focuses on substance use disorders, concurrent mental health disorders, and innovative models of care. He has led and collaborated on multiple national and international initiatives, including pancanadian multi-site clinical trials. His work has contributed to advancing evidence-based treatments, clinical guidelines, and health system responses for people living with substance use disorders. He is actively involved in Canadian and international collaborations aimed at improving policy, research, and clinical care in substance use-related matters.